Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

The emergence of drug resistance limits the efficacy of targeted therapies in human tumors.
The prevalent view is that resistance is a fait accompli: when treatment is initiated, cancers …

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …

The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient
and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond …

Simple Summary Colorectal carcinoma is characterized by intratumoral heterogeneity that
can be assessed by radiogenomics. Radiomics, high-throughput quantitative data extracted …

Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with
mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer …

Purpose: Current glioma diagnostic guidelines call for molecular profiling to stratify patients
into prognostic and treatment subgroups. In case the tumor tissue is inaccessible …

Inactivation of beta-2 microglobulin (B2M) is considered a determinant of resistance to
immune checkpoint inhibitors (ICPi) in melanoma and lung cancers. In contrast, B2M loss …

Purpose: Genomic instability is a hallmark of cancer and targeting DNA damage response
(DDR) is emerging as a promising therapeutic strategy in different solid tumors. The …